Unaudited financial results for the quarter and nine months ended December 31, 2025, is submitted
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Agarwals Eye Hospital reported Q3 FY26 revenue of ₹116.22 Cr, up ~22% YoY from ₹95.11 Cr. Net profit for the quarter surged ~66% YoY to ₹17.28 Cr from ₹10.40 Cr, with EBITDA at ₹37.14 Cr vs ₹27.93 Cr. For nine months FY26, revenue rose ~18% YoY to ₹350.86 Cr and net profit grew ~39% to ₹53.86 Cr. The board also approved shifting the registered office within Chennai limits (from Buhari Towers to Austin Nagar, Alwarpet) effective Feb 5, 2026. Statutory auditor S.R. Batliboi & Associates LLP issued a clean (unmodified) limited review report. The company also noted a proposed amalgamation with holding company Dr Agarwal's Health Care Limited and a ₹70 Cr preferential issue to the same holding company completed in September 2025.
Strong Q3 performance with revenue and profit growth well above sector trends, likely to be viewed positively by shareholders. The registered office shift is administrative with no operational impact, while the ongoing amalgamation with the holding company is a key corporate event to watch. The auditor change and related-party preferential issue are governance items investors may flag.